Cyclacel Pharmaceuticals (CYCC) 3.26 $CYCC
Nasopharyngeal Cancer - Pipeline Review, H1 2014: 6 Company and 17 Drugs Profiled
M2 - Wed May 07, 10:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tlk7p9/nasopharyngeal) has announced the addition of the "Nasopharyngeal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Nasopharyngeal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngeal Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Merck & Co., Inc. - Astex Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals Inc. - National Cancer Centre Singapore Drug Profiles: - nimotuzumab - MK-2206 - CYC-202 - Autologous Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes [carboplatin] [gemcitabine] - Modified Vaccinia Ankara Vaccine - Cytokine-Induced Killer Cells [cisplatin] [gemcitabine] - Icotinib [cisplatin] [paclitaxel] Radiation Therapy - EBV-Specific T-Lymphocytes - LMP Specific Cytotoxic T-Lymphocytes - HLA Matched Allogeneic Virus Specific Cytotoxic T Lymphocytes - EBV-Specific CTL Therapy - Therapeutic p53 Gene Agent - EBV-nRNA - AT-13387 - Imidazoles - LMP2-TCR Gene Therapy - RO-5203280 For more information visit http://www.researchandmarkets.com/research/tl...pharyngeal
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014: Includes 126 Company breakdowns
M2 - Wed May 07, 8:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v5fq8h/acute_myelocytic) has announced the addition of the "Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - 4SC AG - AB Science - AIMM Therapeutics B.V. - AROG Pharmaceuticals LLC - Boehringer Ingelheim GmbH - Coronado Biosciences, Inc. - Critical Outcome Technologies Inc. - CureTech Ltd. - Cyclacel Pharmaceuticals Inc. - ERYtech Pharma - Egenix, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EntreChem, S.L. - EntreMed, Inc. - EpiZyme, Inc. - Esperance Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Formula Pharmaceuticals, Inc. - Gamida Cell Ltd. - Genentech, Inc. - medac GmbH For more information visit http://www.researchandmarkets.com/research/v5...myelocytic
Cyclacel Pharmaceuticals to Release 2014 First Quarter Financial Results
GlobeNewswire - Tue May 06, 3:23PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce financial results for the first quarter ended March 31, 2014 on Tuesday, May 13, 2014. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day.
New Japanese Patents Issued Covering Sapacitabine Pharmaceutical Formulations and Combination Treatments
GlobeNewswire - Mon May 05, 8:42AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced that the Japanese Patent and Trademark Office issued two patents broadening the exclusivity of sapacitabine, the Company's lead clinical candidate. Japanese Patent 5443763 claims novel pharmaceutical formulations of sapacitabine. Japanese Patent 5457196 claims methods of treating cancer comprising sapacitabine in combination with histone deacetylase (HDAC) inhibitors. Equivalent patents have been granted in the United States and other countries.
Global Glomerulonephritis Therapeutics Pipeline Review 2014 - Analysis of 7 Companies & 9 Drug Profiles
M2 - Wed Apr 23, 8:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sgzlr3/glomerulonephritis) has announced the addition of the "Glomerulonephritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Glomerulonephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glomerulonephritis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Glomerulonephritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glomerulonephritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glomerulonephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glomerulonephritis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Cyclacel Pharmaceuticals Inc. - Toray Industries, Inc. - Hansa Medical AB - Pharmalink AB - Indus Biotech Private Limited - China Medical System Holdings Limited - Avexxin AS Drug Profiles - budesonide - simvastatin - CYC-065 - CMS010-26 - EndoS - Small Molecule to Inhibit Vitamin K Epoxide Reductase for Glomerulonephritis - AVX-235 - Drug For Rapidly Progressive Glomerulonephritis - INDUS-903 For more information visit http://www.researchandmarkets.com/research/sg...onephritis
Cyclacel Pharmaceuticals concludes offering of USD10m of common shares
M2 - Thu Apr 10, 7:01AM CDT
US-based biopharmaceutical company Cyclacel Pharmaceuticals (NasdaqGM:CYCC) (NasdaqCM:CYCCP) revealed on Wednesday the completion of its offering of 2,857,143 shares of its common stock.
Independent Investigators Present Non-Clinical Data Providing Rationale for Sapacitabine Combination Treatment With Bcr-Abl Inhibitors in CML
GlobeNewswire - Thu Apr 10, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced that independent investigators reported non-clinical data supporting the combination potential of Cyclacel's oral sapacitabine with Bcr-Abl inhibitors, including imatinib and ponatinib, in chronic myeloid leukemia (CML) cell lines. The data were reported in a poster presentation at the 2014 Annual Meeting of the American Association for Cancer Research (AACR) held April 5-9, 2014 in San Diego.
Cyclacel Pharmaceuticals, Inc. Announces Closing of $10 Million Underwritten Offering
GlobeNewswire - Wed Apr 09, 3:05PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today announced that it has closed the previously announced underwritten offering of 2,857,143 shares of its common stock at a price to the public of $3.50 per share for gross proceeds of approximately $10.0 million. In addition, the Company has granted the underwriters a 30-day option to purchase an additional 428,571 shares of common stock to cover over-allotments, if any.
Cyclacel Pharmaceuticals Announces $10 Million Underwritten Offering
GlobeNewswire - Fri Apr 04, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today announced the pricing of an underwritten public offering of 2,857,143 shares of its common stock to institutional and other investors at a price to the public of $3.50 per share. In connection with the offering, Cyclacel has granted the underwriters a 30-day option to purchase up to an additional 428,571 shares of common stock to cover over-allotments, if any. All of the shares of common stock in this offering are to be sold by Cyclacel.
Cyclacel Pharmaceuticals to offer common stock in public offering
M2 - Fri Apr 04, 5:21AM CDT
Biopharmaceutical company Cyclacel Pharmaceuticals (NasdaqGM:CYCC) (NasdaqCM:CYCCP) said on Thursday that it plans to issue shares of its common stock in a public offering.
Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Apr 03, 3:21PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today announced that it intends to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. The Company intends to use the net proceeds from this offering for funding the continued development of its most advanced product candidate, sapacitabine, in a randomized study of patients with myelodysplastic syndromes (MDS), and general corporate purposes. All of the shares in this offering are to be sold by Cyclacel. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Cyclacel Pharmaceuticals' net loss widens to USD19.5m in 2013
M2 - Wed Mar 26, 6:07AM CDT
US-based Cyclacel Pharmaceuticals (NasdaqGM:CYCC) (NasdaqCM:CYCCP) disclosed on Tuesday a net loss of USD19.5m (USD1.28 per basic and diluted common share) for the year ended 31 December 2013.
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Tue Mar 25, 3:30PM CDT
European Expansion of SEAMLESS Phase 3 Study Initiated; Potentially Trebling Participating Sites
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Mar 13, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company" , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce fourth quarter and full year 2013 financial results on Tuesday, March 25, 2014. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day.
Cyclacel Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company" , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the 16th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City, New York. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs on Monday, February 10, 2014 at 11:00 a.m. Eastern in the Duke of Windsor room.
Investors look to Lighten Up on Shares of Cyclacel Pharmaceuticals, Shares Down 6.2% (CYCC)
Comtex SmarTrend(R) - Mon Jan 27, 12:46PM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's worst performing low-priced stocks, down 6.2% to $3.60 on 1.4x average daily volume. Cyclacel Pharmaceuticals has traded 384,000 shares thus far today, vs. average volume of 284,000 shares per day. The stock has underperformed the Dow (-6.2% to the Dow's -0.2%) and underperformed the S&P 500 (-6.2% to the S&P's -0.5%) during today's trading.
Ubiquiti inks distribution agreement with Ingram Micro
M2 - Thu Jan 16, 8:22AM CST
Ubiquiti Networks, Inc. (NASDAQ: UBNT) said it has announced a US distribution agreement with Ingram Micro Inc. (NYSE: IM).
Cyclacel Reviews 2013 Achievements and Announces Key Business Objectives for 2014
GlobeNewswire - Mon Jan 13, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today reviewed 2013 achievements and provided an outline of the Company's key clinical development objectives for 2014, which will be highlighted at the Company's presentation during the Biotech Showcase(TM) 2014 Conference at 9:30 a.m. PST, Monday, Jan. 13, 2014, at the Parc 55 Wyndham Hotel - Union Square at 55 Cyril Magnin Street in San Francisco.
Cyclacel Pharmaceuticals to Present at Biotech Showcase(TM) 2014 Conference
GlobeNewswire - Mon Jan 06, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company" , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the Biotech Showcase 2014 conference being held at Parc 55 Wyndham San Francisco - Union Square at 55 Cyril Magnin Street, San Francisco, Calif. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs at 9:30 a.m. PST on Monday, January 13, 2014.
Cyclacel Pharmaceuticals Down 10.2%, Shares Slide into the Red (CYCC)
Comtex SmarTrend(R) - Mon Dec 09, 11:43AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's worst performing low-priced stocks, down 10.2% to $4.32 on 1.4x average daily volume. Thus far today, Cyclacel Pharmaceuticals has traded 487,000 shares, vs. average volume of 342,000 shares per day. The stock has underperformed the Dow (-10.2% to the Dow's 0.1%) and underperformed the S&P 500 (-10.2% to the S&P's 0.3%) during today's trading.
Nasopharyngeal Cancer - Pipeline Review, H1 2014: 6 Company and 17 Drugs Profiled
M2 - Wed May 07, 10:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tlk7p9/nasopharyngeal) has announced the addition of the "Nasopharyngeal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Nasopharyngeal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngeal Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Merck & Co., Inc. - Astex Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals Inc. - National Cancer Centre Singapore Drug Profiles: - nimotuzumab - MK-2206 - CYC-202 - Autologous Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes [carboplatin] [gemcitabine] - Modified Vaccinia Ankara Vaccine - Cytokine-Induced Killer Cells [cisplatin] [gemcitabine] - Icotinib [cisplatin] [paclitaxel] Radiation Therapy - EBV-Specific T-Lymphocytes - LMP Specific Cytotoxic T-Lymphocytes - HLA Matched Allogeneic Virus Specific Cytotoxic T Lymphocytes - EBV-Specific CTL Therapy - Therapeutic p53 Gene Agent - EBV-nRNA - AT-13387 - Imidazoles - LMP2-TCR Gene Therapy - RO-5203280 For more information visit http://www.researchandmarkets.com/research/tl...pharyngeal
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014: Includes 126 Company breakdowns
M2 - Wed May 07, 8:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v5fq8h/acute_myelocytic) has announced the addition of the "Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - 4SC AG - AB Science - AIMM Therapeutics B.V. - AROG Pharmaceuticals LLC - Boehringer Ingelheim GmbH - Coronado Biosciences, Inc. - Critical Outcome Technologies Inc. - CureTech Ltd. - Cyclacel Pharmaceuticals Inc. - ERYtech Pharma - Egenix, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EntreChem, S.L. - EntreMed, Inc. - EpiZyme, Inc. - Esperance Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Formula Pharmaceuticals, Inc. - Gamida Cell Ltd. - Genentech, Inc. - medac GmbH For more information visit http://www.researchandmarkets.com/research/v5...myelocytic
Cyclacel Pharmaceuticals to Release 2014 First Quarter Financial Results
GlobeNewswire - Tue May 06, 3:23PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce financial results for the first quarter ended March 31, 2014 on Tuesday, May 13, 2014. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day. New Japanese Patents Issued Covering Sapacitabine Pharmaceutical Formulations and Combination Treatments
GlobeNewswire - Mon May 05, 8:42AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced that the Japanese Patent and Trademark Office issued two patents broadening the exclusivity of sapacitabine, the Company's lead clinical candidate. Japanese Patent 5443763 claims novel pharmaceutical formulations of sapacitabine. Japanese Patent 5457196 claims methods of treating cancer comprising sapacitabine in combination with histone deacetylase (HDAC) inhibitors. Equivalent patents have been granted in the United States and other countries.
Global Glomerulonephritis Therapeutics Pipeline Review 2014 - Analysis of 7 Companies & 9 Drug Profiles
M2 - Wed Apr 23, 8:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sgzlr3/glomerulonephritis) has announced the addition of the "Glomerulonephritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Glomerulonephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glomerulonephritis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Glomerulonephritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glomerulonephritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glomerulonephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glomerulonephritis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Cyclacel Pharmaceuticals Inc. - Toray Industries, Inc. - Hansa Medical AB - Pharmalink AB - Indus Biotech Private Limited - China Medical System Holdings Limited - Avexxin AS Drug Profiles - budesonide - simvastatin - CYC-065 - CMS010-26 - EndoS - Small Molecule to Inhibit Vitamin K Epoxide Reductase for Glomerulonephritis - AVX-235 - Drug For Rapidly Progressive Glomerulonephritis - INDUS-903 For more information visit http://www.researchandmarkets.com/research/sg...onephritis
Cyclacel Pharmaceuticals concludes offering of USD10m of common shares
M2 - Thu Apr 10, 7:01AM CDT
US-based biopharmaceutical company Cyclacel Pharmaceuticals (NasdaqGM:CYCC) (NasdaqCM:CYCCP) revealed on Wednesday the completion of its offering of 2,857,143 shares of its common stock.
Independent Investigators Present Non-Clinical Data Providing Rationale for Sapacitabine Combination Treatment With Bcr-Abl Inhibitors in CML
GlobeNewswire - Thu Apr 10, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced that independent investigators reported non-clinical data supporting the combination potential of Cyclacel's oral sapacitabine with Bcr-Abl inhibitors, including imatinib and ponatinib, in chronic myeloid leukemia (CML) cell lines. The data were reported in a poster presentation at the 2014 Annual Meeting of the American Association for Cancer Research (AACR) held April 5-9, 2014 in San Diego.
Cyclacel Pharmaceuticals, Inc. Announces Closing of $10 Million Underwritten Offering
GlobeNewswire - Wed Apr 09, 3:05PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today announced that it has closed the previously announced underwritten offering of 2,857,143 shares of its common stock at a price to the public of $3.50 per share for gross proceeds of approximately $10.0 million. In addition, the Company has granted the underwriters a 30-day option to purchase an additional 428,571 shares of common stock to cover over-allotments, if any.
Cyclacel Pharmaceuticals Announces $10 Million Underwritten Offering
GlobeNewswire - Fri Apr 04, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today announced the pricing of an underwritten public offering of 2,857,143 shares of its common stock to institutional and other investors at a price to the public of $3.50 per share. In connection with the offering, Cyclacel has granted the underwriters a 30-day option to purchase up to an additional 428,571 shares of common stock to cover over-allotments, if any. All of the shares of common stock in this offering are to be sold by Cyclacel.
Cyclacel Pharmaceuticals to offer common stock in public offering
M2 - Fri Apr 04, 5:21AM CDT
Biopharmaceutical company Cyclacel Pharmaceuticals (NasdaqGM:CYCC) (NasdaqCM:CYCCP) said on Thursday that it plans to issue shares of its common stock in a public offering.
Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Apr 03, 3:21PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today announced that it intends to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. The Company intends to use the net proceeds from this offering for funding the continued development of its most advanced product candidate, sapacitabine, in a randomized study of patients with myelodysplastic syndromes (MDS), and general corporate purposes. All of the shares in this offering are to be sold by Cyclacel. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Cyclacel Pharmaceuticals' net loss widens to USD19.5m in 2013
M2 - Wed Mar 26, 6:07AM CDT
US-based Cyclacel Pharmaceuticals (NasdaqGM:CYCC) (NasdaqCM:CYCCP) disclosed on Tuesday a net loss of USD19.5m (USD1.28 per basic and diluted common share) for the year ended 31 December 2013.
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Tue Mar 25, 3:30PM CDT
European Expansion of SEAMLESS Phase 3 Study Initiated; Potentially Trebling Participating Sites
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Mar 13, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce fourth quarter and full year 2013 financial results on Tuesday, March 25, 2014. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day. Cyclacel Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the 16th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City, New York. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs on Monday, February 10, 2014 at 11:00 a.m. Eastern in the Duke of Windsor room. Investors look to Lighten Up on Shares of Cyclacel Pharmaceuticals, Shares Down 6.2% (CYCC)
Comtex SmarTrend(R) - Mon Jan 27, 12:46PM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's worst performing low-priced stocks, down 6.2% to $3.60 on 1.4x average daily volume. Cyclacel Pharmaceuticals has traded 384,000 shares thus far today, vs. average volume of 284,000 shares per day. The stock has underperformed the Dow (-6.2% to the Dow's -0.2%) and underperformed the S&P 500 (-6.2% to the S&P's -0.5%) during today's trading.
Ubiquiti inks distribution agreement with Ingram Micro
M2 - Thu Jan 16, 8:22AM CST
Ubiquiti Networks, Inc. (NASDAQ: UBNT) said it has announced a US distribution agreement with Ingram Micro Inc. (NYSE: IM).
Cyclacel Reviews 2013 Achievements and Announces Key Business Objectives for 2014
GlobeNewswire - Mon Jan 13, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today reviewed 2013 achievements and provided an outline of the Company's key clinical development objectives for 2014, which will be highlighted at the Company's presentation during the Biotech Showcase(TM) 2014 Conference at 9:30 a.m. PST, Monday, Jan. 13, 2014, at the Parc 55 Wyndham Hotel - Union Square at 55 Cyril Magnin Street in San Francisco.
Cyclacel Pharmaceuticals to Present at Biotech Showcase(TM) 2014 Conference
GlobeNewswire - Mon Jan 06, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the Biotech Showcase 2014 conference being held at Parc 55 Wyndham San Francisco - Union Square at 55 Cyril Magnin Street, San Francisco, Calif. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs at 9:30 a.m. PST on Monday, January 13, 2014. Cyclacel Pharmaceuticals Down 10.2%, Shares Slide into the Red (CYCC)
Comtex SmarTrend(R) - Mon Dec 09, 11:43AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's worst performing low-priced stocks, down 10.2% to $4.32 on 1.4x average daily volume. Thus far today, Cyclacel Pharmaceuticals has traded 487,000 shares, vs. average volume of 342,000 shares per day. The stock has underperformed the Dow (-10.2% to the Dow's 0.1%) and underperformed the S&P 500 (-10.2% to the S&P's 0.3%) during today's trading.
